PHAT Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 7.7%, SMA50 -5.89%, SMA200 16.63%). The stock’s 14-day RSI is 54.76 (neutral), while the ATR of 0.94 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -25.94% below its high and over 513.57% above its low. Average 10-day trading volume of 1.36 million shares is slightly above the 3-month average of 1.22 million, indicating heightened recent market interest.

Phathom Pharmaceuticals, Inc. generated EPS of -$3.81 over the past year. Five-year average earnings growth is 12.5%. The latest quarter delivered EPS of -$0.37. The next quarter is forecast at -$0.40. Next year's EPS is expected at -$21.16. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 3 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $26.00 to $18.00. The high target offers 137.01% upside. The low target suggests 64.08% downside. The mean target is $23.75. This offers 116.5% upside. Phathom Pharmaceuticals, Inc. earnings surprise history is a mixed track record. The quarter that ended April 30, 2026, missed forecasts by 117.65%. The prior quarter beat by -49.9%. Over the last six quarters, Apple has recorded several small beats. These include -38.76% in March 06, 2025.

Phathom Pharmaceuticals, Inc. has 70.94 million shares outstanding. The public float is 51.19 million shares, elevated short interest at 30.66% of float. This equals 13.17 million shares. The short ratio is 12.44 days. Institutional investors hold 95.21% of the float. Insiders own 4.73%. TAKEDA PHARMACEUTICAL CO LTD holds 3.76 million shares, Socks David A has 1.21 million shares and Curran Terrie has 360.46 thousand shares.

Phathom Pharmaceuticals, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$4.10. This means the shares are trading below this model’s fair value.

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) closed at $10.97 USD, losing -$0.08 (-0.72%) from the previous close of $11.05. The stock is currently mid-range between its 52-week high and low $7.61 and $18.31. With a market capitalization of about $874.92 million, Phathom Pharmaceuticals, Inc. is classified as a small-cap and shows lower-than-market volatility (beta ~0.49). Key stats such as the average daily volume over the past year has been around 1.26 million shares, volume is running light vs its 52-week average. Headquartered in Florham Park, NJ, Phathom Pharmaceuticals, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Steven L. Basta, the company employs approximately 371 people and listed since October 25, 2019. Phathom Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, dedicated to advancing and commercializing therapies for gastrointestinal ailments.

Phathom Pharmaceuticals, Inc. trades at a P/E ratio of -5.18, slightly below the S&P 500 average, with a price-to-sales ratio of 4.28 and a price-to-book ratio of -2.68 indicating negative book value, which may reflect financial stress. The P/FCF stands at -9.0, also above market averages.

Our AI price prediction model suggests that Phathom Pharmaceuticals, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 6.56%, with price expected at $11.69 by July 29, 2026, within a range of $11.15 to $12.30 3-Month Outlook: Projected rise of 19.69%, reaching $13.13 by October 12, 2026, with a range of $12.79 to $13.50. 1-Year Outlook: Projected gain of 129.08%, with price at $25.13 by July 15, 2027, within a range of $11.28 to $39.19.

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) shares are down -14.71% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Phathom Pharmaceuticals, Inc. trading at a premium to the broader market with a P/E of -5.18. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $28.18, suggesting 156.88% upside. Our AI forecast model points to short-term strength (6.56% over two weeks), a medium-term rise (19.69% over three months), and a longer-term gain (129.08% over one year), with expected trading ranges indicating moderate volatility.